Login to Your Account

Financings Roundup

Tetralogic Closes $23M Second Tranche in Series C

By Catherine Shaffer

Thursday, January 6, 2011
Tetralogic Pharmaceuticals Corp., of Malvern, Pa., is wasting no time putting its series C financing to work. The company closed a second and final tranche of $23 million, out of a total $37 million, and has already dosed its first cohort in a Phase Ib/IIa open-label, non-randomized, dose-escalation safety and tolerability study of TL32711 for advanced or metastatic solid tumors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription